The therapeutic community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial decrease in body mass and improve metabolic functio